Evotec
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average and near the bottom of the universe on momentum.
- Signal has read STRONG SELL for 6 months.
- Recent price momentum is -43.6% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2849 U.S. stocks StockVane covers.
Last computed: 2026-11-21 14:27 UTC
Data coverage: 4 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation N/A
How expensive the stock is versus earnings, sales and its own 5-year history.
Not enough data to grade this factor.
Growth B+
How fast revenue, profit and free cash flow are compounding.
| Revenue CAGR (3Y) | 1.6% | Better than 33% |
| Net income CAGR (3Y) | 36.8% | Better than 84% |
| Free cash flow CAGR (3Y) | 33.4% | Better than 76% |
Profitability D
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 14.5% | Better than 11% |
| Operating margin | -7.1% | Better than 16% |
| Net margin | -13.1% | Better than 14% |
| Return on equity | -11.7% | Better than 19% |
| Return on invested capital | -7.3% | Better than 19% |
Momentum D-
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -31.6% | Better than 17% |
| 6-month return | -56.4% | Better than 5% |
| 12-month return (ex latest month) | -48.1% | Better than 3% |
| Distance below 52-week high | 65.9% | Better than 8% |
Financial Health D
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 2.1x | Better than 57% |
| Debt to assets | 26.1% | Better than 47% |
| Interest coverage | -5.0x | Better than 17% |
| Free cash flow / net income | 1.5% | Better than 0% |
Analyst View N/A
What the Street thinks: share of Buy ratings and upside to the average target.
Not enough data to grade this factor.
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 1.45
- Open
- 1.38
- Day range
- 1.32 - 1.38
- Avg price
- 1.36
- Volume
- 77.59K
- Turnover
- 105.13K
- Turnover ratei
- 0.03%
- Volume ratioi
- 1.25
- Amplitudei
- 4.14%
- 52-week rangei
- 1.32 - 3.87
Valuation
- P/Ei
- -4.15
- P/E (TTM)i
- -2.38
- P/Bi
- 0.67
- EPSi
- -0.32
- Book value / shi
- 1.98
- Net profit
- -113.01M
- Net assets
- 703.67M
Share structure
- Market cap
- 469.11M
- Float capi
- 388.02M
- Shares out
- 355.39M
- Float sharesi
- 293.95M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2021-11-04
65.9% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-986.49K net over the window
Short interest
- Shares short
- 63.32K
- % of floati
- 0.02%
- Days to coveri
- 1.00
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Evotec (EVO)?
Evotec last traded at 1.32. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Evotec's market cap?
About 469.11M.
What is the P/E ratio of Evotec?
The trailing twelve-month P/E is -2.38, below its own 5-year average of 87.42 — toward the top of its historical range (76.78% percentile). See the Valuation tab for the full history.
Does Evotec pay a dividend?
Evotec does not currently pay a regular dividend.
Is Evotec a buy according to analysts?
The consensus of 1 analysts is a Buy rating, with an average 12-month price target of 5.00, which implies 278.8% upside from the current price. This is not investment advice.
What is Evotec's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Evotec a E (Strong Sell). Below its 200-day average and near the bottom of the universe on momentum. Not investment advice.
Quote time 2026-11-20 17:47:50 · For reference only, not investment advice and not tailored to your situation.
Evotec discussion 0 comments